Sfoglia per Autore
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
2004-01-01 MICHIELI P; MAZZONE M; BASILICO C; CAVASSA S; SOTTILE A; NALDINI L; P. COMOGLIO
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice
2004-01-01 MAZZONE M; BASILICO C; CAVASSA S; PENNACCHIETTI S; RISIO M; NALDINI L; PM COMOGLIO; MICHIELI P
HGF-MSP chimera protects kidneys from ischemia-reperfusion injury.
2007-01-01 Xue F; Isaka Y; Takahara T; Imamura R; Suzuki C; Ichimaru N; Michieli P; Takahara S.
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met
2008-01-01 Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis
2008-01-01 Cassano M; Biressi S; Finan A; Benedetti L; Omes C; Boratto R; Martin F; Allegretti M; Broccoli V; Cusella De Angelis G; Comoglio PM; Basilico C; Torrente Y; Michieli P; Cossu G; Sampaolesi M
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis
2008-01-01 Takahara T; Xue F; Mazzone M; Yata Y; Nonome K; Kanayama M; Kawai K; Pisacane AM; Takahara S; Li XK; Comoglio PM; Sugiyama T; Michieli P
HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF
2009-01-01 CRISTINA BASILICO; PAOLO MICHIELI; PAOLO CARMINATI; PAOLO MARIA COMOGLIO
Expression and Functional Regulation of Myoglobin in Epithelial Cancers
2009-01-01 Flonta SE; Arena S; Pisacane A; Michieli P; Bardelli A
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis
2009-01-01 Galluzzo M; Pennacchietti S; Rosano S; Comoglio PM; Michieli P
Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe?
2009-01-01 Michieli P
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody
2010-01-01 G. Pacchiana;C. Chiriaco;M. C. Stella;F. Petronzelli;R. D. Santis;M. Galluzzo;P. Carminati;P. M. Comoglio;P. Michieli;E. Vigna
Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene
2011-01-01 P. Comoglio; E. Vigna; P. Michieli
MAGIC-FACTOR, A PARTIAL AGONIST OF MET, ACTS AS A SAFE HEPATOTROPHIC CYTOKINE
2011-01-01 T. Takahara; K. Kawai; T. Sugiyama; M. Asahi; P. Michieli
Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes?
2013-01-01 Michieli P; Di Nicolantonio F
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
2013-01-01 C. Basilico;S. Pennacchietti;E. Vigna;C. Chiriaco;S. Arena;A. Bardelli;D. Valdembri;G. Serini;P. Michieli
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.
2013-01-01 Michieli P;Basilico C;Pennacchietti S
New antibody fragments, compositions and uses thereof
2014-01-01 Elisa Vigna; Paolo Michieli; Paolo Maria Comoglio
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.
2014-01-01 Vigna E;Pacchiana G;Chiriaco C;Cignetto S;Fontani L;Michieli P;Comoglio PM
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
2014-01-01 Van Schaeybroeck S;Kalimutho M;Dunne PD;Carson R;Allen W;Jithesh PV;Redmond KL;Sasazuki T;Shirasawa S;Blayney J;Michieli P;Fenning C;Lenz HJ;Lawler M;Longley DB;Johnston PG
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.
2014-01-01 Pennacchietti S;Cazzanti M;Bertotti A;Rideout WM ;Han M;Gyuris J;Perera T;Comoglio PM;Trusolino L;Michieli P
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor | 2004 | MICHIELI P; MAZZONE M; BASILICO C; CAVASSA S; SOTTILE A; NALDINI L; P. COMOGLIO | |
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice | 2004 | MAZZONE M; BASILICO C; CAVASSA S; PENNACCHIETTI S; RISIO M; NALDINI L; PM COMOGLIO; MICHIELI P | |
HGF-MSP chimera protects kidneys from ischemia-reperfusion injury. | 2007 | Xue F; Isaka Y; Takahara T; Imamura R; Suzuki C; Ichimaru N; Michieli P; Takahara S. | |
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met | 2008 | Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P | |
Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis | 2008 | Cassano M; Biressi S; Finan A; Benedetti L; Omes C; Boratto R; Martin F; Allegretti M; Broccoli V; Cusella De Angelis G; Comoglio PM; Basilico C; Torrente Y; Michieli P; Cossu G; Sampaolesi M | |
Metron factor-1 prevents liver injury without promoting tumor growth and metastasis | 2008 | Takahara T; Xue F; Mazzone M; Yata Y; Nonome K; Kanayama M; Kawai K; Pisacane AM; Takahara S; Li XK; Comoglio PM; Sugiyama T; Michieli P | |
HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF | 2009 | CRISTINA BASILICO; PAOLO MICHIELI; PAOLO CARMINATI; PAOLO MARIA COMOGLIO | |
Expression and Functional Regulation of Myoglobin in Epithelial Cancers | 2009 | Flonta SE; Arena S; Pisacane A; Michieli P; Bardelli A | |
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis | 2009 | Galluzzo M; Pennacchietti S; Rosano S; Comoglio PM; Michieli P | |
Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? | 2009 | Michieli P | |
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody | 2010 | G. Pacchiana;C. Chiriaco;M. C. Stella;F. Petronzelli;R. D. Santis;M. Galluzzo;P. Carminati;P. M. Comoglio;P. Michieli;E. Vigna | |
Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene | 2011 | P. Comoglio; E. Vigna; P. Michieli | |
MAGIC-FACTOR, A PARTIAL AGONIST OF MET, ACTS AS A SAFE HEPATOTROPHIC CYTOKINE | 2011 | T. Takahara; K. Kawai; T. Sugiyama; M. Asahi; P. Michieli | |
Targeted therapies: Tivantinib-a cytotoxic drug in MET inhibitor's clothes? | 2013 | Michieli P; Di Nicolantonio F | |
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET | 2013 | C. Basilico;S. Pennacchietti;E. Vigna;C. Chiriaco;S. Arena;A. Bardelli;D. Valdembri;G. Serini;P. Michieli | |
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response. | 2013 | Michieli P;Basilico C;Pennacchietti S | |
New antibody fragments, compositions and uses thereof | 2014 | Elisa Vigna; Paolo Michieli; Paolo Maria Comoglio | |
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. | 2014 | Vigna E;Pacchiana G;Chiriaco C;Cignetto S;Fontani L;Michieli P;Comoglio PM | |
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. | 2014 | Van Schaeybroeck S;Kalimutho M;Dunne PD;Carson R;Allen W;Jithesh PV;Redmond KL;Sasazuki T;Shirasawa S;Blayney J;Michieli P;Fenning C;Lenz HJ;Lawler M;Longley DB;Johnston PG | |
Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. | 2014 | Pennacchietti S;Cazzanti M;Bertotti A;Rideout WM ;Han M;Gyuris J;Perera T;Comoglio PM;Trusolino L;Michieli P |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile